

# Validation data for Anti-hTIGIT-hlgG1

<https://www.invivogen.com/anti-htigit-mab>


For research use only

Version 19J24-ED

Anti-hTIGIT-hlgG1 is a recombinant monoclonal antibody (mAb) featuring a variable region that recognizes human TIGIT and the constant region of the native human IgG1 isotype (hlgG1). TIGIT is an important immune checkpoint, specifically expressed on natural killer (NK) cells, and range of T cell subsets. Upon binding to its ligand, TIGIT directly reduces NK cytotoxicity as well as T cell activation and proliferation. The binding of Anti-hTIGIT-IgG1 has been validated using engineered TIGIT-expressing Raji cells (**Figure 1**).

## Binding of Anti-hTIGIT-hlgG1 to target cells

The binding of Anti-hTIGIT-hlgG1 to cell-expressed TIGIT has been validated using engineered TIGIT-expressing Raji cells (Raji-hTIGIT) compared to Raji-null cells, which do not express TIGIT. A clear shift to the right of the fluorescence peak is noted when Anti-hTIGIT-hlgG1 is incubated with Raji-hTIGIT (right) and not Raji-null (left) cells, indicating strong and specific binding.



**Figure 1:** Anti-hTIGIT-hlgG1 (2 µg) was added to Raji-null (negative control) and Raji-hTIGIT cells (500 000 cells/ml) and incubated at room temperature for 30 minutes. Following this, a secondary antibody, PE, was added and incubated again at room temperature for 30 minutes. The binding affinity was then measured using flow cytometry.

### TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3-622-34-80

E-mail: [info@invivogen.com](mailto:info@invivogen.com)